^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MSB0254

    i
    Other names: MSB0254
    Associations

    News

    Trials
    Company:
    Transcenta
    Drug class:
    VEGF-A inhibitor, VEGFR-2 inhibitor, VEGF-C inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma. (PubMed, Biochem Biophys Res Commun)
    The VEGFR2 monoclonal antibody could inhibit the angiogenesis and tumor growth of GBM by blocking the signaling pathway mediated by VEGFR2. It may become a new supplementary treatment for GBM.
    Journal
    |
    CD34 (CD34 molecule) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
    |
    KDR expression
    |
    MSB0254